Rigel Pharmaceuticals, Inc. RIGL

RIGL Company Overview

Rigel Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of small‑molecule therapies for hematologic disorders, cancer, and immune‑mediated diseases. The company’s business centers on advancing targeted therapies that address areas of unmet medical need, with revenue primarily derived from commercialized prescription medicines and collaboration arrangements.

Rigel’s primary revenue drivers are its commercial products, most notably TAVALISSE® (fostamatinib), an oral spleen tyrosine kinase (SYK) inhibitor approved for adult patients with chronic immune thrombocytopenia (ITP), and REZLIDHIA® (olutasidenib), an oral IDH1 inhibitor approved for relapsed or refractory acute myeloid leukemia (AML). The company serves specialty physician markets, including hematologists and oncologists, and positions itself as a focused commercial-stage biotech with expertise in kinase inhibition and precision oncology. Rigel was founded in 1996 and evolved from a discovery‑oriented research company into a commercial-stage organization following regulatory approvals beginning in 2018.